Home > Healthcare > Medical Devices > Diagnostic Devices > Fusion Biopsy Market

Fusion Biopsy Market Share

Report ID: GMI12341
Published Date: Nov 2024
Report Format: PDF

Download Free Sample

Fusion Biopsy Market Share

The market is competitive, with a mix of large multinationals like Koninklijke Philips N.V., Focal Healthcare, and Koelis leading in innovation and extensive product portfolios. Regional companies and new entrants, particularly from APAC, are also making significant strides. The market is characterized by frequent technological advancements, such as improved precision, enhanced real-time guidance, and increased workflow efficiency, which drive ongoing product development. Strategic partnerships, mergers, and acquisitions are common as companies seek to expand market reach and enhance their technological capabilities.

Fusion Biopsy Market Companies

Prominent players operating in the fusion biopsy industry include:

Canon Medical Systems
CIVCO Medical Solutions
Eigen Health
Esaote SpA
Exact imaging
Focal Healthcare
GE HealthCare
Koelis
Koninklijke Philips N.V.
MedCom
Merit Medical Systems
Siemens Healthineers

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global fusion biopsy industry was valued at USD 829.1 million in 2024 and is expected to grow at a 9.9% CAGR from 2025 to 2034, driven by the increasing prevalence of prostate cancer and supportive government policies.

The devices segment generated USD 703.1 million in 2024, with rising investments in MRI-ultrasound fusion systems due to their enhanced diagnostic accuracy in prostate cancer detection.

The North America fusion biopsy industry recorded USD 367.1 million in 2024 and is anticipated to grow at a 9.2% CAGR from 2025 to 2034, driven by advanced healthcare infrastructure and high prostate cancer incidence.

Key players in the sector include Canon Medical Systems, CIVCO Medical Solutions, Eigen Health, Esaote SpA, Exact Imaging, Focal Healthcare, GE HealthCare, Koelis, Koninklijke Philips N.V., and MedCom.